An interventional study of Low FODMAP Diet and High FODMAP Diet in Irritable Bowel Syndrome (IBS), Constipation - Functional and Bloating, sponsored by Mahidol University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Mahidol University · Not applicable, Interventional, and Treatment
This clinical study aims to evaluate the effects of a low FODMAP diet compared to a high FODMAP diet in patients with Irritable Bowel Syndrome (IBS) and Functional Constipation (FC) with predominant bloating. The study is a randomized, double-blind, controlled trial designed to assess whether a diet low in fermentable carbohydrates can improve bloating symptoms, gut microbiota composition, intestinal gas production, and metabolic outputs.
Patients meeting the Rome IV criteria for IBS or FC with persistent bloating will be enrolled and randomly assigned to receive either a low or high FODMAP diet for two weeks. Meals will be standardized to control FODMAPs composition, ensuring that FODMAP content is the primary variable.
The primary endpoint is the proportion of participants with a ≥30% reduction in bloating severity, measured using the Visual Analog Scale (VAS). Secondary outcomes include changes in global IBS symptoms, abdominal pain, bowel movements, stool consistency, microbiota diversity, hydrogen/methane gas production, and metabolomic profiles.
This study will contribute to the growing body of evidence supporting dietary management in disorders of gut-brain interaction (DGBI), particularly in bloating-predominant IBS and FC, and will provide insights into the mechanisms linking diet, gut microbiota, and symptom improvement.
Irritable Bowel Syndrome (IBS) and Functional Constipation (FC) are chronic Disorders of Gut-Brain Interaction (DGBI) characterized by altered motility, visceral hypersensitivity, dysbiosis, and central nervous system processing abnormalities. Bloating is a challenging and distressing symptom that often persists despite standard pharmacological treatments.
The low FODMAP diet has been widely studied as a dietary approach to alleviate IBS symptoms. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are poorly absorbed short-chain carbohydrates that increase osmolarity, promote intestinal gas production, and alter gut microbiota, leading to bloating and discomfort. Although studies support the effectiveness of the low FODMAP diet, existing research lacks controlled, blinded trials assessing its impact on bloating-specific symptoms and related physiological markers.
This study addresses these gaps by using a double-blind, controlled design with rigorously standardized meals containing well-defined FODMAP content. It will assess clinical outcomes, gut microbiota composition, gas production, and metabolomic changes to elucidate the mechanisms underlying the diet's effects.
Study Design This is a randomized, double-blind, controlled trial conducted at a single center. Participants will be assigned to receive either a low FODMAP or a high FODMAP diet for two weeks.
Participants:
Adults ≥18 years diagnosed with IBS or FC with persistent bloating based on Rome IV criteria.
Intervention:
Standardized meal plans containing either low FODMAP or high FODMAP content.
Randomization:
Computer-generated block randomization (block of 4)
Blinding:
Investigators, study staff, and participants will remain blinded to the dietary allocation.
Primary Outcome:
≥30% reduction in bloating severity on the VAS scale.
Secondary Outcomes:
Changes in global IBS symptoms (IBS-SSS) or constipation symptoms (PAC-Sym) Abdominal pain (VAS) stool frequency, and consistency (Bristol Stool Form Scale). Gut microbiota diversity and composition (16S rRNA sequencing). Intestinal gas production (hydrogen/methane breath test). Metabolomic analysis (short-chain fatty acids, urine histamine, azelaic acid). Use of rescue medications for symptom relief.
Study Procedures
Baseline Assessment:
Demographic data, medical history, and dietary habits (7-day food diary). Baseline bloating severity, stool consistency, and quality of life (IBS-QoL, PAC-QoL).
Microbiota, breath test, and metabolomic sampling.
Intervention Phase (2 Weeks):
Participants consume standardized low or high FODMAP meals (3 main meals + 1 snack/day).
Daily recording of symptoms, bowel movements, and use of rescue medications.
Follow-up Assessments:
Week 1: Phone follow-up to assess adherence and symptom progression. Week 2: Final clinical and laboratory assessments (identical to baseline). Data collection for statistical analysis comparing treatment effects.
Statistical Analysis Primary endpoint (bloating reduction) analyzed using Chi-square/Fisher's exact test.
Secondary outcomes analyzed with paired t-tests, Mann-Whitney U tests, and logistic regression.
Microbiota diversity assessed using Shannon index, beta diversity, and PERMANOVA testing.
Significance and Impact This study will provide high-quality evidence on the effectiveness of the low FODMAP diet for bloating-predominant IBS and FC, addressing critical knowledge gaps. By integrating clinical, microbiota, and metabolomic data, it will enhance understanding of diet-microbiota interactions and their role in symptom modulation.
1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.
This study's planned enrollment of 34 is below the median of 71 across 853 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →Mahidol University is the lead sponsor of 730 studies on the registry; 118 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will follow a low FODMAP diet for two weeks, consuming standardized meals with minimal fermentable carbohydrates. Meals match the high FODMAP diet in appearance to maintain blinding.
Other: Low FODMAP Diet
Participants will follow a high FODMAP diet for two weeks, consuming standardized meals with high fermentable carbohydrates. Meals match the low FODMAP diet in appearance to maintain blinding.
Other: High FODMAP Diet
A standardized diet containing low levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), designed to reduce bloating and gastrointestinal symptoms. Meals are pre-prepared, calorie-matched, and visually identical to those in the high FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence monitored through food diaries and photos.
A standardized diet containing high levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) to assess its impact on bloating and gastrointestinal symptoms. Meals are calorie-matched and visually identical to those in the low FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence tracked through food diaries and photos.
Change in Bloating Severity (VAS)
The primary outcome is the change in bloating severity, measured using the Visual Analog Scale (VAS). The VAS score ranges from 0 (no bloating) to 10 (severe bloating), with higher scores indicating worse bloating symptoms. Participants will record daily bloating scores throughout the intervention period. The proportion of participants achieving a ≥30% decrease in bloating severity from baseline will be analyzed.
Time frame: Baseline to 2 weeks (End of Intervention)
Reduction in Global IBS Symptoms (IBS-SSS)
Change in IBS Symptom Severity Score (IBS-SSS) from baseline, assessing overall IBS symptom burden, abdominal pain, bloating, and bowel habit changes. The IBS-SSS scale ranges from 0 to 500, with higher scores indicating more severe IBS symptoms.
Time frame: Baseline to 2 weeks
Change in Abdominal Pain (VAS)
Change in abdominal pain severity, measured using the Visual Analog Scale (VAS). The VAS scale ranges from 0 (no pain) to 10 (severe pain), with higher scores indicating worse pain severity. Participants will record daily pain scores, and the difference between baseline and post-intervention scores will be analyzed.
Time frame: Baseline to 2 weeks
Change in Stool Frequency and Consistency
Change in bowel movement frequency and stool consistency, assessed using the Bristol Stool Form Scale (BSFS). Stool frequency will be recorded as the number of bowel movements per day. Stool consistency will be graded using the BSFS scale (1-7): 1-2: Hard stools (constipation) 3-4: Normal stools 5-7: Loose stools (diarrhea) Higher BSFS scores indicate looser stool consistency. The difference between baseline and post-intervention values will be analyzed.
Time frame: Baseline to 2 weeks
Changes in Gut Microbiota Composition
Alterations in gut microbiota diversity and abundance (16S rRNA sequencing).
Time frame: Baseline to 2 weeks
Change in Hydrogen Gas Production (Lactulose Breath Test)
Change in exhaled hydrogen (H₂) levels, measured via lactulose breath test in parts per million (ppm). Higher hydrogen levels indicate increased fermentation by colonic microbiota.
Time frame: Baseline to 2 weeks
Change in Methane Gas Production (Lactulose Breath Test)
Change in exhaled methane (CH₄) levels, measured via lactulose breath test in parts per million (ppm). Elevated methane levels are associated with slow colonic transit and constipation.
Time frame: Baseline to 2 weeks
Use of Rescue Medications
Frequency and dosage of antispasmodics, prokinetics, or laxatives used for symptom relief.
Time frame: Baseline to 2 weeks
Change in Psychological Symptoms (DASS-21)
Change in Depression, Anxiety, and Stress Scores (DASS-21), a validated self-reported scale measuring psychological distress. The DASS-21 consists of three subscales: Depression (0-21) Anxiety (0-21) Stress (0-21) Each subscale score ranges from 0 (normal) to 21 (severe symptoms), with higher scores indicating greater psychological distress. The total score is calculated by summing individual subscale scores.
Time frame: Baseline to 2 weeks
Change in Quality of Life (IBS-QoL / PAC-QoL)
Change in IBS-specific Quality of Life (IBS-QoL) score, which assesses the impact of IBS on daily activities, emotional well-being, and social functioning. The IBS-QoL score ranges from 0 to 100, with higher scores indicating better quality of life.
Time frame: Baseline to 2 weeks
Patient Satisfaction with Treatment
Overall treatment satisfaction, measured using a Visual Analog Scale (VAS) ranging from 0 to 10: 0 = Completely Dissatisfied 10 = Completely Satisfied Higher scores indicate greater satisfaction with treatment. The difference between baseline and post-intervention scores will be analyzed.
Time frame: Baseline to 2 weeks
Change in Patient-Reported Constipation Symptoms (PAC-SYM)
Change in Patient Assessment of Constipation-Symptoms (PAC-SYM) score, evaluating constipation-related symptoms, including stool consistency, discomfort, and straining. The PAC-SYM scale ranges from 0 to 48, with higher scores indicating worse constipation symptoms.
Time frame: Baseline to 2 weeks
Change in Short-Chain Fatty Acids (SCFAs) Levels
Change in fecal short-chain fatty acids (SCFAs), including acetic acid, propionic acid, and butyric acid, measured in μmol/g stool. Higher SCFA levels indicate greater microbial fermentation activity.
Time frame: Baseline to 2 weeks
Change in Urine Histamine Levels
Change in urine histamine concentration, measured in μg/mL urine, assessing histamine metabolism related to gut inflammation and microbiota activity. Higher levels indicate increased histamine production.
Time frame: Baseline to 2 weeks
Change in Urine Azelaic Acid Levels
Change in urine azelaic acid concentration, measured in μg/mL urine, assessing microbial metabolic changes associated with gut dysbiosis and inflammation. Higher levels indicate altered microbial metabolism.
Time frame: Baseline to 2 weeks
Change in Constipation-Specific Quality of Life (PAC-QoL)
Change in Patient Assessment of Constipation-Quality of Life (PAC-QoL) score, evaluating the impact of constipation on daily life, physical discomfort, psychological well-being, and social aspects. The PAC-QoL score ranges from 0 to 100, with higher scores indicating better quality of life.
Time frame: Baseline to 2 weeks
No study locations are listed for this record.
Plan to share: No
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mahidol University